Abstract
Have you a compound in your lab, which was not successful against the designed target, or a drug that is no more attractive? The drug repurposing represents the right way to reconsider them. It can be defined as the modern and rationale approach of the traditional methods adopted in drug discovery, based on the knowledge, insight and luck, alias known as serendipity. This repurposing approach can be applied both in silico and in wet. In this review we report the molecular modeling facilities that can be of huge support in the repurposing of drugs and/or unsuccessful lead compounds. In the last decades, different methods were proposed to help the scientists in drug design and in drug repurposing. The steps strongly depend on the approach applied. It could be a ligand or a structure based method, correlated to the use of specific means. These processes, starting from a compound with potential therapeutic properties and a sizeable number of toxicity passed tests, can successfully speed up the very slow development of a molecule from bench to market. Herein, we discuss the facilities available to date, classifying them by methods and types. We have reported a series of databases, ligand and structure stand-alone software, and of web-based tools, which are free accessible to scientific community. This review does not claim to be exhaustive, but can be of interest to help in drug repurposing through in silico methods, as a valuable tool for the medicinal chemistry community.
Keywords: Drug design, Drug repositioning, Drug repurposing, In silico approaches, Lead compound, Ligand based, Structure based.
Current Topics in Medicinal Chemistry
Title:The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives
Volume: 16 Issue: 19
Author(s): Annamaria Martorana, Ugo Perricone and Antonino Lauria
Affiliation:
Keywords: Drug design, Drug repositioning, Drug repurposing, In silico approaches, Lead compound, Ligand based, Structure based.
Abstract: Have you a compound in your lab, which was not successful against the designed target, or a drug that is no more attractive? The drug repurposing represents the right way to reconsider them. It can be defined as the modern and rationale approach of the traditional methods adopted in drug discovery, based on the knowledge, insight and luck, alias known as serendipity. This repurposing approach can be applied both in silico and in wet. In this review we report the molecular modeling facilities that can be of huge support in the repurposing of drugs and/or unsuccessful lead compounds. In the last decades, different methods were proposed to help the scientists in drug design and in drug repurposing. The steps strongly depend on the approach applied. It could be a ligand or a structure based method, correlated to the use of specific means. These processes, starting from a compound with potential therapeutic properties and a sizeable number of toxicity passed tests, can successfully speed up the very slow development of a molecule from bench to market. Herein, we discuss the facilities available to date, classifying them by methods and types. We have reported a series of databases, ligand and structure stand-alone software, and of web-based tools, which are free accessible to scientific community. This review does not claim to be exhaustive, but can be of interest to help in drug repurposing through in silico methods, as a valuable tool for the medicinal chemistry community.
Export Options
About this article
Cite this article as:
Martorana Annamaria, Perricone Ugo and Lauria Antonino, The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives, Current Topics in Medicinal Chemistry 2016; 16 (19) . https://dx.doi.org/10.2174/1568026616666160216153457
DOI https://dx.doi.org/10.2174/1568026616666160216153457 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Current Vascular Pharmacology Preface [Hot Topic: Exogenous Factors Affecting Cardiovascular and Hematological Targets (Guest Editor: R. Manjunatha Kini)]
Current Drug Targets - Cardiovascular & Hematological Disorders Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases
Current Pharmaceutical Design Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy
Current Pharmacogenomics Strategies for Enhancing Progenitor Cell Mobilization and Function in Diabetes
Current Vascular Pharmacology Sex Differences in Oxidative Stress Biomarkers
Current Drug Targets Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update
CNS & Neurological Disorders - Drug Targets Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Therapeutic Potential of Voltage Gated Calcium Channels
Mini-Reviews in Medicinal Chemistry Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
Current Drug Targets In-vitro Antioxidant activity of ‘Aswathy Chooranam’- a Siddha Drug
Current Traditional Medicine Left Ventricular Hypertrophy in ADPKD: Changing Demographics
Current Hypertension Reviews Deprescribing Antipsychotic Medications in Psychotic Disorders: How and Why?
Current Psychiatry Reviews Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Should all Hypertensive Patients be Screened for Primary Aldosteronism?
Current Hypertension Reviews VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Medicinal Properties of Mangiferin, Structural Features, Derivative Synthesis, Pharmacokinetics and Biological Activities
Mini-Reviews in Medicinal Chemistry